Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma

Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma

Malignant pleural mesothelioma (MPM) is a rare and highly aggressive tumor. Nivolumab showed durable antitumor effect in patients with recurrent MPM and was approved for those patients in Japan in 2018. Immune related adverse event (irAE) is occurred in various organs and is suggestive to be related...

Full description

Bibliographic Details
Main Authors: Jun Sakakibara-Konishi, Mineyoshi Sato, Michiko Takimoto Sato, Kohei Kasahara, Masahiro Onozawa, Hidenori Mizugaki, Eiki Kikuchi, Hajime Asahina, Naofumi Shinagawa, Satoshi Konno
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:Respiratory Medicine Case Reports
Subjects:
Malignant pleural mesothelioma
Nivolumab
Immune thrombocytopenia
Online Access:http://www.sciencedirect.com/science/article/pii/S221300712030383X

Internet

http://www.sciencedirect.com/science/article/pii/S221300712030383X

Similar Items